Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
4.000
-0.010 (-0.25%)
At close: Apr 28, 2026, 4:00 PM EDT
3.840
-0.160 (-4.00%)
After-hours: Apr 28, 2026, 6:30 PM EDT
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
$347,568
Profits / Employee
-$295,166
Market Cap
291.55M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Coherus Oncology | 147 |
| AC Immune | 122 |
| Zentalis Pharmaceuticals | 106 |
| C4 Therapeutics | 104 |
| Editas Medicine | 87 |
| Compugen | 75 |
| Cybin | 50 |
CLLS News
- 1 day ago - Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting - GlobeNewsWire
- 15 days ago - Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform - GlobeNewsWire
- 21 days ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 5 weeks ago - Cellectis Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 6 weeks ago - Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - GlobeNewsWire
- 4 months ago - Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
- 4 months ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire